Revisiting Hormone Therapy: From Fear to Confidence

A physician in Novi who is open to treating woman for menopause

By Robert Zaid, DO

When I graduated from medical school in 2005, the medical community was still reeling from the results of the Women’s Health Initiative (WHI) and the Nurses’ Health Study. These landmark studies had cast long shadows over hormone replacement therapy, particularly estrogen and testosterone. As young physicians, we were taught to avoid hormone correction out of fear that we might inadvertently increase the risk of heart disease, stroke, or cancer. Despite watching patients struggle with the effects of low testosterone and menopause, many of us hesitated to act.

For men, symptoms of low testosterone—fatigue, brain fog, loss of muscle mass, and low libido—were often dismissed as normal aging. For women, menopause was something to “get through,” not something to treat aggressively. It was frustrating. We knew our patients were suffering, and instinctively, we believed hormone optimization could help. But the fear ingrained in our training overrode our clinical intuition.

Over the years, that fear has gradually given way to a more nuanced understanding. Thanks to newer, more targeted studies, I’ve grown increasingly confident discussing hormone therapy with patients, particularly as I’ve engaged with emerging data and committed to staying current.

One recent landmark in this evolving field is the 2023 TRAVERSE (also known as TRANSEND) study, which followed more than 5,000 men aged 45 to 80 with low testosterone and preexisting cardiovascular risk factors. The findings were striking: testosterone therapy did not increase the risk of major cardiovascular events. As the study concluded, “Testosterone-replacement therapy was noninferior to placebo with respect to the incidence of major adverse cardiac events.” For many of us who had been cautiously optimistic, this was a game-changer.

For women, estrogen therapy has also undergone a reassessment. We now understand that timing, formulation, and delivery method matter. When prescribed appropriately—especially early in the menopausal transition—hormone therapy can improve quality of life without the previously assumed risks. It’s not about ignoring safety concerns; it’s about putting those concerns into context with up-to-date science and individualized care.

As a practicing physician, I’m now far more comfortable initiating these conversations. I look at the whole patient—their symptoms, goals, family history, and risk profile—and I engage in open, honest discussions about the potential risks and benefits of hormone therapy. Patients are grateful to be heard, and I’m grateful to be in a place where I can offer real solutions based on better evidence.

At this point in my career I am now a physician working in Novi who is comfortable prescribing hormone therapy for woman in perimenopause and menopause.  I am constantly learning and studying as this field is ever changing.

Looking back, I understand why we were cautious. But we’re in a different era now—one that embraces complexity and encourages shared decision-making. What once felt risky now feels responsible when done thoughtfully and informed by current research.

Medicine evolves, and so do we. I’m proud to say that my approach has matured along with the science, and my patients are better off because of it.

Dr. Robert Zaid practices family medicine and has evolved his practice into a  that is unhurried and makes him more available to his patients.  If you would like to learn more click below.